Clinical trials: Hepatocellular Carcinoma Resectable
- Condition Hepatocellular Carcinoma Resectable
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Liver Cancer
DX-8951f in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
- Trial name
- NCT00004108
- Testing
- exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo